RE: Going Blue & well oversold!27 Aug 2020 14:20
With thanks to Vitec on ADVFN re the Motley Fool
We would like to introduce you to a great Britsh company Synairgen. Based in Southampton, CEO Richard Marsden and his team have been working tirelessly to find an effective treatment for Covid 19. In March 2020, the company embarked on a double blinded placbo trial in 101 patients to show whether a natural protein Interferon would have any affect on patients showing mild symptoms of Covid 19. In July of this year the results were published and the results were extremely good. To back up the hospital trial the company is also undertaking a home trial (120 patients) where patients can administer the drug and be monitored at home.
Mr Marsden also announced earlier in the Summer that he would be in a position to release data from the COPD trial that they had undertaken. If positive this data will underpin further the data from the hospital trial.
So what does the future hold for Synairgen? The shares have had a meteoric rise from a low of 6p to £2.59 and many investors have been rewarded for their faith with this rise. Recently, the shares have fallen approximately 20%. So is this a good time to be buying shares in Synairgen? This question depends on your risk/reward ratio and whether you believe that the company has run its course. To make a better informed decision you have to take into account all of the facts as they have presentated themselves and possible future developments.
Synairgen through their conducted hospital trial have proven that Interferons and specifically their drug SNG 001 works and has shown very good results. This is also backed up by other worldwide studies, research and trials that show the effacacy of Interferons in tackling Covid 19.
Synairgen have undertaken a home trial. The results from this should also show good results in line with the hospital trial. These results will be published in the future.
The COPD trial intially undertaken to be with 120 patients but stopped due to Covid and therefore only has 109 pateints data is to be released shortly and should again show the effacacy of the drug and the relief it gives to patients in releaving them of their symptoms.
Synairgen have been working with the regulators to get emergency approval so that SNG 001 can be used as an effective treatment in the Covid arena and save lives.
Synairgen is also we believe working with a larger Pharma partner and has been manufacturing millions of doses so that SNG 001 can be rolled out immediately upon approval.
There is no doubt that Synairgen is not a one trick pony and that all of their colours are firmly attached to the Covid mast. The major risk, that SNG 001 did not work has been removed. There may be some further turbulence going forward with the share price as investors grapple and understand all of the data and the impact it may have but we remain buyers of the share as we believe that further validation and regulatory approval will enhance the share pri